Atlas Trials

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

Clinical trial NCT03180840 · COMPLETED

Trial details

NCT number
NCT03180840
Sponsor
Protalix
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Fabry Disease
Start date
2017-07-10
Primary completion
2020-08-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.